Technology
Jack Henry & Associates, Inc. Reports First Quarter Fiscal 2025 Results
Published
2 years agoon
By
First quarter summary:
GAAP revenue increased 5.2% and GAAP operating income increased 14.0% for the fiscal three months ended September 30, 2024, compared to the prior fiscal year quarter.Non-GAAP adjusted revenue increased 5.3% and non-GAAP adjusted operating income increased 1.6% for the fiscal three months ended September 30, 2024, compared to the prior fiscal year quarter.1GAAP EPS was $1.63 per diluted share for the fiscal three months ended September 30, 2024, compared to $1.39 per diluted share in the prior fiscal year quarter.Cash and cash equivalents were $43 million at September 30, 2024, and $31 million at September 30, 2023.Debt outstanding related to credit facilities was $140 million at September 30, 2024, and $245 million at September 30, 2023.
Full year fiscal 2025 guidance:2
Current
GAAP
Low
High
Revenue
$2,369
$2,391
Operating margin3
23.0 %
23.2 %
EPS
$5.78
$5.87
Non-GAAP4
Adjusted revenue
$2,353
$2,375
Adjusted operating margin
22.7 %
22.8 %
MONETT, Mo., Nov. 5, 2024 /PRNewswire/ — Jack Henry & Associates, Inc. (Nasdaq: JKHY), a leading financial technology provider, today announced results for fiscal first quarter ended September 30, 2024.
According to Greg Adelson, President and CEO, “We are pleased to report another quarter of solid financial performance, which was slightly better than the outlook provided in August for FY Q1. Our sales team maintained positive momentum in the quarter with a new record sales attainment for Q1 and increased our sales pipeline to an all-time high. We had an outstanding Jack Henry Connect conference last month in Phoenix, where we strengthened relationships with clients and prospects and demonstrated our execution over the past year. We are energized and remain focused on our key differentiators: culture, service, and innovation.”
1 See tables below on page 4 reconciling non-GAAP financial measures to GAAP.
2 The full fiscal year guidance assumes no acquisitions or dispositions are made during fiscal year 2025.
3Operating margin is calculated by dividing operating income by revenue.
4 See tables below on page 7 reconciling fiscal year 2025 GAAP to non-GAAP guidance.
5See table below on page 12 reconciling net income to non-GAAP EBITDA.
Operating Results
Revenue, operating expenses, operating income, and net income for the three months ended September 30, 2024, compared to the three months ended September 30, 2023, were as follows:
Revenue
(Unaudited, In Thousands)
Three Months Ended
September 30,
%
Change
2024
2023
Revenue
Services and Support
$ 356,679
$ 342,205
4.2 %
Percentage of Total Revenue
59.3 %
59.9 %
Processing
244,303
229,163
6.6 %
Percentage of Total Revenue
40.7 %
40.1 %
REVENUE
$ 600,982
$ 571,368
5.2 %
Services and support revenue increased for the three months ended September 30, 2024, primarily driven by growth in data processing and hosting revenue of 12.6%, partially offset by a decrease in license and hardware revenue of 35.9%. Processing revenue increased for the three months ended September 30, 2024, primarily driven by growth in card revenue of 5.1% and transaction and digital revenue of 10.9%. Other drivers were increases in payment processing and remote capture and ACH revenues.For the three months ended September 30, 2024, core segment revenue increased 4.9%, payments segment revenue increased 6.3%, complementary segment revenue increased 6.4%, and corporate and other segment revenue decreased 10.2%. For the three months ended September 30, 2024, core segment non-GAAP adjusted revenue increased 5.2%, payments segment non-GAAP adjusted revenue increased 5.9%, complementary segment non-GAAP adjusted revenue increased 7.1%, and corporate and other non-GAAP adjusted segment revenue decreased 10.3% (see revenue lines of segment break-out tables on pages 5 and 6 below for a reconciliation of segment non-GAAP adjusted revenue to GAAP segment revenue).
Operating Expenses and Operating Income
(Unaudited, In Thousands)
Three Months Ended
September 30,
%
Change
2024
2023
Cost of Revenue
$ 343,432
$ 323,002
6.3 %
Percentage of Total Revenue6
57.1 %
56.5 %
Research and Development
39,686
36,892
7.6 %
Percentage of Total Revenue6
6.6 %
6.5 %
Selling, General, and Administrative
66,588
78,774
(15.5) %
Percentage of Total Revenue6
11.1 %
13.8 %
OPERATING EXPENSES
449,706
438,668
2.5 %
OPERATING INCOME
$ 151,276
$ 132,700
14.0 %
Operating Margin6
25.2 %
23.2 %
Cost of revenue increased for the three months ended September 30, 2024, primarily due to higher direct costs generally consistent with increases in the related lines of revenue, higher personnel costs including benefits expenses from an increase in employee headcount in the trailing twelve months, higher internal licenses and fees from increased deployments and prices, and a rise in amortization from capital development projects placed into service in the trailing twelve months.Research and development expense increased for the three months ended September 30, 2024, primarily due to higher personnel costs (net of capitalization) including benefits expenses from an increase in employee headcount in the trailing twelve months.Selling, general, and administrative expense decreased for the three months ended September 30, 2024, primarily due to the decrease in non-recurring costs when compared to the prior fiscal year quarter.
Net Income
(Unaudited, In Thousands,
Except Per Share Data)
Three Months Ended
September 30,
%
Change
2024
2023
Income Before Income Taxes
$ 156,798
$ 133,248
17.7 %
Provision for Income Taxes
37,607
31,569
19.1 %
NET INCOME
$ 119,191
$ 101,679
17.2 %
Diluted earnings per share
$ 1.63
$ 1.39
17.1 %
Effective tax rates for the three months ended September 30, 2024, and 2023, were 24.0% and 23.7%, respectively.
According to Mimi Carsley, CFO and Treasurer, “For the first quarter of the fiscal year, revenue and operating margins were aligned with our plan and expectations and we continue to expect stronger performance in the second half of our fiscal year. Our private cloud revenue grew over 11% and processing services continued to drive strong revenue growth at over 6%, each contributing to our overall revenue expansion of over 5% and operating income increase of 2% on a non-GAAP basis.”
6Operating margin is calculated by dividing operating income by revenue. Operating margin plus operating expense components as a percentage of total revenue may not equal 100% due to rounding.
Impact of Non-GAAP Adjustments
The tables below show our revenue, operating income, and net income for the three months ended September 30, 2024, compared to the three months ended September 30, 2023, excluding the impacts of deconversions and the VEDIP program expense.*
(Unaudited, In Thousands)
Three Months Ended
September 30,
%
Change
2024
2023
GAAP Revenue**
$ 600,982
$ 571,368
5.2 %
Adjustments:
Deconversion revenue
(3,697)
(4,136)
NON-GAAP ADJUSTED REVENUE**
$ 597,285
$ 567,232
5.3 %
GAAP Operating Income
$ 151,276
$ 132,700
14.0 %
Adjustments:
Operating income from deconversions
(3,495)
(3,755)
VEDIP program expense*
—
16,443
NON-GAAP ADJUSTED OPERATING INCOME
$ 147,781
$ 145,388
1.6 %
Non-GAAP Adjusted Operating Margin***
24.7 %
25.6 %
GAAP Net Income
$ 119,191
$ 101,679
17.2 %
Adjustments:
Net income from deconversions
(3,495)
(3,755)
VEDIP program expense*
—
16,443
Tax impact of adjustments****
839
(3,045)
NON-GAAP ADJUSTED NET INCOME
$ 116,535
$ 111,322
4.7 %
*The VEDIP program expense for the fiscal three months ended September 30, 2024, was related to a Company voluntary separation program offered to certain eligible employees beginning in July 2023.
**GAAP revenue is comprised of services and support and processing revenues (see page 2). Reducing services and support revenue by deconversion revenue for the three months ended September 30, 2024, and 2023 which was $3,697 for the current fiscal year quarter and $4,136 for the prior fiscal year quarter, results in non-GAAP adjusted services and support revenue growth of 4.4% quarter over quarter. There were no non-GAAP adjustments to processing revenue for the three months ended September 30, 2024, or 2023.
***Non-GAAP adjusted operating margin is calculated by dividing non-GAAP adjusted operating income by non-GAAP adjusted revenue.
****The tax impact of adjustments is calculated using a tax rate of 24% for the three months ended September 30, 2024, and 2023. The tax rate for non-GAAP adjustment items takes a broad look at our recurring tax adjustments and applies them to non-GAAP revenue that does not have its own specific tax impacts.
The tables below show the segment break-out of revenue and cost of revenue for each period presented, as adjusted for the items above, and include a reconciliation to non-GAAP adjusted operating income presented above.
Three Months Ended September 30, 2024
(Unaudited, In Thousands)
Core
Payments
Complementary
Corporate
and Other
Total
GAAP REVENUE
$ 195,624
$ 211,923
$ 171,702
$ 21,733
$ 600,982
Non-GAAP adjustments*
(1,287)
(1,914)
(473)
(23)
(3,697)
NON-GAAP ADJUSTED REVENUE
194,337
210,009
171,229
21,710
597,285
GAAP COST OF REVENUE
81,420
113,020
65,967
83,025
343,432
Non-GAAP adjustments*
(37)
(18)
(60)
—
(115)
NON-GAAP ADJUSTED COST OF REVENUE
81,383
113,002
65,907
83,025
343,317
GAAP SEGMENT INCOME
$ 114,204
$ 98,903
$ 105,735
$ (61,292)
Segment Income Margin**
58.4 %
46.7 %
61.6 %
(282.0) %
NON-GAAP ADJUSTED SEGMENT INCOME
$ 112,954
$ 97,007
$ 105,322
$ (61,315)
Non-GAAP Adjusted Segment Income Margin**
58.1 %
46.2 %
61.5 %
(282.4) %
Research and Development
39,686
Selling, General, and Administrative
66,588
Non-GAAP adjustments unassigned to a segment***
(87)
NON-GAAP TOTAL ADJUSTED OPERATING EXPENSES
449,504
NON-GAAP ADJUSTED OPERATING INCOME
$ 147,781
*Revenue non-GAAP adjustments for all segments were deconversion revenue. Cost of revenue non-GAAP adjustments for all segments were deconversion costs.
**Segment income margin is calculated by dividing segment income by revenue for each segment. Non-GAAP adjusted segment income margin is calculated by dividing non-GAAP adjusted segment income by non-GAAP adjusted revenue for each segment.
***Non-GAAP adjustments unassigned to a segment were selling, general, and administrative deconversion costs.
Three Months Ended September 30, 2023
(Unaudited, In Thousands)
Core
Payments
Complementary
Corporate
and Other
Total
GAAP REVENUE
$ 186,439
$ 199,358
$ 161,366
$ 24,205
$ 571,368
Non-GAAP adjustments*
(1,665)
(1,006)
(1,451)
(14)
(4,136)
NON-GAAP ADJUSTED REVENUE
184,774
198,352
159,915
24,191
567,232
GAAP COST OF REVENUE
75,927
108,826
60,957
77,292
323,002
Non-GAAP adjustments*
(103)
(47)
(119)
(1)
(270)
NON-GAAP ADJUSTED COST OF REVENUE
75,824
108,779
60,838
77,291
322,732
GAAP SEGMENT INCOME
$ 110,512
$ 90,532
$ 100,409
$ (53,087)
Segment Income Margin
59.3 %
45.4 %
62.2 %
(219.3) %
NON-GAAP ADJUSTED SEGMENT INCOME
$ 108,950
$ 89,573
$ 99,077
$ (53,100)
Non-GAAP Adjusted Segment Income Margin
59.0 %
45.2 %
62.0 %
(219.5) %
Research and Development
36,892
Selling, General, and Administrative
78,774
Non-GAAP adjustments unassigned to a segment** ***
(16,554)
NON-GAAP TOTAL ADJUSTED OPERATING EXPENSES
421,844
NON-GAAP ADJUSTED OPERATING INCOME
$ 145,388
*Revenue non-GAAP adjustments for all segments were deconversion revenues. Cost of revenue non-GAAP adjustments for all segments were deconversion costs.
**Non-GAAP adjustments unassigned to a segment were selling, general, and administrative deconversion costs of $(111) and VEDIP program expense of $(16,443).
***The VEDIP program expense for the fiscal three months ended September 30, 2023, was related to a Company voluntary separation program offered to certain eligible employees beginning in July 2023.
The table below shows our GAAP to non-GAAP guidance for the fiscal year ending June 30, 2025. Fiscal year 2025 non-GAAP guidance excludes the impacts of deconversion revenue and related operating expenses and assumes no acquisitions or dispositions are made during the fiscal year.
GAAP to Non-GAAP GUIDANCE (In Millions, except per share data)
Annual FY25
Low
High
GAAP REVENUE
$ 2,369
$ 2,391
Growth
6.9 %
7.9 %
Deconversions*
$ 16
$ 16
NON-GAAP ADJUSTED REVENUE**
$ 2,353
$ 2,375
Non-GAAP Adjusted Growth
7.0 %
8.0 %
GAAP OPERATING EXPENSES
$ 1,823
$ 1,836
Growth
5.6 %
6.4 %
Deconversion costs*
$ 3
$ 3
NON-GAAP ADJUSTED OPERATING EXPENSES**
$ 1,820
$ 1,833
Non-GAAP Adjusted Growth
6.7 %
7.4 %
GAAP OPERATING INCOME
$ 546
$ 555
Growth
11.6 %
13.3 %
GAAP OPERATING MARGIN
23.0 %
23.2 %
NON-GAAP ADJUSTED OPERATING INCOME**
$ 533
$ 542
Non-GAAP Adjusted Growth
8.2 %
9.9 %
NON-GAAP ADJUSTED OPERATING MARGIN
22.7 %
22.8 %
GAAP EPS***
$ 5.78
$ 5.87
Growth
10.6 %
12.3 %
Non-GAAP EPS***
$ 5.65
$ 5.74
Growth
7.3 %
9.0 %
*Deconversion revenue and related operating expenses are based on actual results for the three months ended September 30, 2024, and estimates for the remainder of fiscal year 2025, based on the lowest actual recent historical results. See the Company’s Form 8-K filed with the Securities and Exchange Commission on October 28, 2024.
**GAAP to Non-GAAP revenue, operating expenses, and operating income may not foot due to rounding.
***The GAAP to Non-GAAP EPS reconciliation table is below on page 13.
Balance Sheet and Cash Flow Review
Cash and cash equivalents were $43 million at September 30, 2024, and $31 million at September 30, 2023.Trade receivables were $307 million at September 30, 2024, compared to $289 million at September 30, 2023.The Company had $140 million of borrowings at September 30, 2024 compared to $245 million of borrowings at September 30, 2023.Deferred revenue decreased to $320 million at September 30, 2024, compared to $333 million at September 30, 2023.Stockholders’ equity increased to $1,925 million at September 30, 2024, compared to $1,660 million at September 30, 2023.
*See table below for Net Cash Provided by Operating Activities and on page 12 for Return on Average Shareholders’ Equity. Tables reconciling the non-GAAP measures Free Cash Flow and Return on Invested Capital (ROIC) to GAAP measures are also on page 12. See the Use of Non-GAAP Financial Information section below for the definitions of Free Cash Flow and ROIC.
The following table summarizes net cash from operating activities:
(Unaudited, In Thousands)
Three Months Ended September 30,
2024
2023
Net income
$ 119,191
$ 101,679
Depreciation
11,273
12,052
Amortization
39,221
37,183
Change in deferred income taxes
(4,087)
(10,178)
Other non-cash expenses
6,678
7,037
Change in receivables
26,373
72,519
Change in deferred revenue
(69,358)
(66,322)
Change in other assets and liabilities*
(12,395)
3,169
NET CASH FROM OPERATING ACTIVITIES
$ 116,896
$ 157,139
*For the year ended September 30, 2024, includes the change in income taxes of $38,576, the change in accrued expenses of $(23,067), and the change in prepaid expenses, prepaid cost of product and other of $(18,788). For the year ended September 30, 2023, includes the change in income taxes of $39,044, the change in prepaid expenses, prepaid cost of product and other of $(17,356), and the change in accrued expenses of $(17,285).
The following table summarizes net cash from investing activities:
(Unaudited, In Thousands)
Three Months Ended September 30,
2024
2023
Capital expenditures
(12,801)
(7,612)
Proceeds from dispositions
—
852
Purchased software
(2,676)
(2,280)
Computer software developed
(42,259)
(41,486)
Purchase of investments
(2,000)
—
Proceeds from investments
1,000
—
NET CASH FROM INVESTING ACTIVITIES
$ (58,736)
$ (50,526)
The following table summarizes net cash from financing activities:
(Unaudited, In Thousands)
Three Months Ended September 30,
2024
2023
Borrowings on credit facilities
$ 75,000
$ 135,000
Repayments on credit facilities and financing leases
(85,000)
(165,000)
Purchase of treasury stock
—
(20,000)
Dividends paid
(40,104)
(37,863)
Net cash from issuance of stock and tax related to stock-based compensation
(3,128)
474
NET CASH FROM FINANCING ACTIVITIES
$ (53,232)
$ (87,389)
Use of Non-GAAP Financial Information
Generally Accepted Accounting Principles (GAAP) is the term used to refer to the standard framework of guidelines for financial accounting in the United States. GAAP includes the standards, conventions, and rules accountants follow in recording and summarizing transactions in the preparation of financial statements. In addition to reporting financial results in accordance with GAAP, we have provided certain non-GAAP financial measures, including adjusted revenue, adjusted operating income, adjusted segment income, adjusted cost of revenue, adjusted operating expenses, adjusted operating margin, adjusted segment income margin, non-GAAP earnings before interest, taxes, depreciation, and amortization (non-GAAP EBITDA), free cash flow, return on invested capital (ROIC), non-GAAP adjusted net income, and non-GAAP earnings per share (EPS).
We believe non-GAAP financial measures help investors better understand the underlying fundamentals and true operations of our business. Adjusted revenue, adjusted operating income, adjusted operating margin, adjusted segment income, adjusted segment income margin, adjusted cost of revenue, adjusted operating expenses, adjusted net income, and non-GAAP EPS eliminate one-time deconversion revenue and associated costs and the effects of the VEDIP program expense, which management believes are not indicative of the Company’s operating performance. Such adjustments give investors further insight into our performance. Non-GAAP EBITDA is defined as net income attributable to the Company before the effect of interest expense, taxes, depreciation, and amortization, adjusted for net income before the effect of interest expense, taxes, depreciation, and amortization attributable to eliminated one-time deconversions and the VEDIP program expense. Free cash flow is defined as net cash from operating activities, less capitalized expenditures, internal use software, and capitalized software, plus proceeds from the sale of assets. ROIC is defined as net income divided by average invested capital, which is the average of beginning and ending long-term debt and stockholders’ equity for a given period. Management believes that non-GAAP EBITDA is an important measure of the Company’s overall operating performance and excludes certain costs and other transactions that management deems one time or non-operational in nature; free cash flow is useful to measure the funds generated in a given period that are available for debt service requirements and strategic capital decisions; and ROIC is a measure of the Company’s allocation efficiency and effectiveness of its invested capital. For these reasons, management also uses these non-GAAP financial measures in its assessment and management of the Company’s performance.
Non-GAAP financial measures used by the Company may not be comparable to similarly titled non-GAAP measures used by other companies. Non-GAAP financial measures have no standardized meaning prescribed by GAAP and therefore, are unlikely to be comparable with calculations of similar measures for other companies.
Any non-GAAP financial measures should be considered in context with the GAAP financial presentation and should not be considered in isolation or as a substitute for GAAP measures. Reconciliations of the non-GAAP financial measures to related GAAP measures are included.
Quarterly Conference Call
The Company will hold a conference call on November 6, 2024, at 7:45 a.m. Central Time, and investors are invited to listen at www.jackhenry.com. A webcast replay will be available approximately one hour after the event at ir.jackhenry.com/corporate-events-and-presentations and will remain available for one year.
About Jack Henry & Associates, Inc.®
Jack Henry™ (Nasdaq: JKHY) is a well-rounded financial technology company that strengthens connections between financial institutions and the people and businesses they serve. We are an S&P 500 company that prioritizes openness, collaboration, and user centricity — offering banks and credit unions a vibrant ecosystem of internally developed modern capabilities as well as the ability to integrate with leading fintechs. For more than 48 years, Jack Henry has provided technology solutions to enable clients to innovate faster, strategically differentiate, and successfully compete while serving the evolving needs of their accountholders. We empower approximately 7,500 clients with people-inspired innovation, personal service, and insight-driven solutions that help reduce the barriers to financial health. Additional information is available at www.jackhenry.com.
Statements made in this news release that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Because forward-looking statements relate to the future, they are subject to inherent risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, but are not limited to, those discussed in the Company’s Securities and Exchange Commission filings, including the Company’s most recent reports on Form 10-K and Form 10-Q, particularly under the heading Risk Factors. Any forward-looking statement made in this news release speaks only as of the date of the news release, and the Company expressly disclaims any obligation to publicly update or revise any forward-looking statement, whether because of new information, future events or otherwise.
Condensed Consolidated Statements of Income (Unaudited)
(In Thousands, except per share data)
Three Months Ended
September 30,
%
Change
2024
2023
REVENUE
$ 600,982
$ 571,368
5.2 %
Cost of Revenue
343,432
323,002
6.3 %
Research and Development
39,686
36,892
7.6 %
Selling, General, and Administrative
66,588
78,774
(15.5) %
EXPENSES
449,706
438,668
2.5 %
OPERATING INCOME
151,276
132,700
14.0 %
Interest income
8,347
4,745
75.9 %
Interest expense
(2,825)
(4,197)
(32.7) %
Interest Income (Expense), net
5,522
548
907.7 %
INCOME BEFORE INCOME TAXES
156,798
133,248
17.7 %
Provision for Income Taxes
37,607
31,569
19.1 %
NET INCOME
$ 119,191
$ 101,679
17.2 %
Diluted net income per share
$ 1.63
$ 1.39
Diluted weighted average shares outstanding
73,078
73,014
Consolidated Balance Sheet Highlights (Unaudited)
(In Thousands)
September 30,
%
Change
2024
2023
Cash and cash equivalents
$ 43,212
$ 31,467
37.3 %
Receivables
306,660
288,733
6.2 %
Total assets
2,928,511
2,734,223
7.1 %
Accounts payable and accrued expenses
$ 231,713
$ 208,909
10.9 %
Current and long-term debt
140,000
245,000
(42.9) %
Deferred revenue
319,574
333,407
(4.1) %
Stockholders’ equity
1,925,028
1,659,948
16.0 %
Calculation of Non-GAAP Earnings Before Income Taxes, Depreciation and Amortization (Non-GAAP EBITDA)
Three Months Ended
September 30,
%
Change
(in thousands)
2024
2023
Net income
$ 119,191
$ 101,679
Net interest
(5,522)
(548)
Taxes
37,607
31,569
Depreciation and amortization
50,494
49,235
Less: Net income before interest expense, taxes, depreciation and
amortization attributable to eliminated one-time adjustments*
(3,495)
12,688
NON-GAAP EBITDA
$ 198,275
$ 194,623
1.9 %
*The fiscal first quarter 2025 adjustments for net income before interest expense, taxes, depreciation and amortization were for deconversions. The fiscal first quarter 2024 adjustments were for deconversions and the VEDIP program expense and were $(3,755) and $16,443, respectively.
Calculation of Free Cash Flow (Non-GAAP)
Three Months Ended
September 30,
(in thousands)
2024
2023
Net cash from operating activities
$ 116,896
$ 157,139
Capitalized expenditures
(12,801)
(7,612)
Internal use software
(2,676)
(2,280)
Proceeds from sale of assets
—
852
Capitalized software
(42,259)
(41,486)
FREE CASH FLOW
$ 59,160
$ 106,613
Calculation of the Return on Average Shareholders’ Equity
September 30,
(in thousands)
2024
2023
Net income (trailing four quarters)
$ 399,328
$ 361,776
Average stockholder’s equity (period beginning and ending balances)
1,792,488
1,560,543
RETURN ON AVERAGE SHAREHOLDERS’ EQUITY
22.3 %
23.2 %
Calculation of Return on Invested Capital (ROIC) (Non-GAAP)
September 30,
(in thousands)
2024
2023
Net income (trailing four quarters)
$ 399,328
$ 361,776
Average stockholder’s equity (period beginning and ending balances)
1,792,488
1,560,543
Average current maturities of long-term debt and financing leases
(period beginning and ending balances)
45,000
21
Average long-term debt (period beginning and ending balances)
147,500
245,000
Average invested capital
$ 1,984,988
$ 1,805,564
ROIC
20.1 %
20.0 %
GAAP to Non-GAAP EPS Reconciliation Table
FY25 Guidance
GAAP EPS
$5.78-$5.87
Excluded Activity, net of Tax:
Deconversion*
$0.13
Non-GAAP EPS
$5.65-$5.74
*We are not aware of any other discreet adjustments at this time. Deconversion revenue and related operating expenses are based on actual results for fiscal first quarter 2025 and estimates for the remainder of fiscal year 2025, based on the lowest actual recent historical results. See the Company’s Form 8-K filed with the Securities and Exchange Commission on October 28, 2024.
View original content to download multimedia:https://www.prnewswire.com/news-releases/jack-henry–associates-inc-reports-first-quarter-fiscal-2025-results-302296898.html
SOURCE Jack Henry & Associates, Inc.
You may like
Technology
HelloNation Article Highlights Sterile Compounding and Medication Safety With Insights From Compounding Pharmacist Expert Laura Temple
Published
8 minutes agoon
July 21, 2026By
The article explains how sterile compounded medications are prepared to reduce the risk of contamination and support safe, customized treatments.
AZLE, Texas, July 21, 2026 /PRNewswire/ — What does sterile compounding mean for medication safety? HelloNation has published an article explaining how sterile compounding helps pharmacies prepare highly specialized medications while adhering to strict contamination-prevention procedures.
The article features insights from Laura Temple, Compounding Pharmacist Expert and Owner of Laura’s Pharmacy in Azle, Texas. It explains that sterile compounding is a specialized process for preparing medications in carefully controlled environments designed to reduce the risk of contamination. Sterile compounded medications are often used for injections, eye drops, IV medications, and other therapies that require the highest levels of cleanliness and precision.
The HelloNation article explains that sterile compounded medications differ from commercially manufactured drugs because they are prepared individually for a patient’s unique medical needs. Physicians may prescribe compounded prescriptions when a patient requires a customized dosage, a combination medication, or a treatment not commercially available. Because these medications often bypass the body’s natural defenses, medication safety depends on strict preparation standards throughout the compounding process.
The article describes how pharmacies that provide sterile compounding rely on cleanroom environments equipped with filtered-air systems, specialized equipment, and contamination-prevention protocols. Pharmacists and technicians follow detailed gowning, sterilization, and handwashing procedures before handling medication ingredients. These measures are designed to support medication safety by limiting exposure to bacteria, particles, and other contaminants.
According to the article, environmental monitoring also plays a critical role in sterile compounding. Temperature control, air quality testing, and routine equipment inspections help maintain consistent preparation standards. The article notes that sterile compounded medications may undergo additional quality assurance checks before being dispensed to patients. These procedures help support both treatment effectiveness and patient safety.
The HelloNation article also explains that pharmacies performing sterile compounding are expected to follow USP guidelines established for sterile preparation. These USP guidelines outline requirements for cleanroom pharmacy operations, environmental testing, employee training, and quality assurance practices. The article emphasizes that maintaining compliance with USP guidelines helps reinforce contamination prevention and consistent preparation standards for compounded prescriptions.
Patients seeking sterile compounded medications may also look for pharmacies that participate in accreditation programs or are overseen by state boards. The article explains that these programs review safety procedures, documentation practices, and facility standards to help maintain medication safety. Regular environmental monitoring and staff competency evaluations are also identified as important safeguards in sterile compounding operations.
The article further explains that communication between pharmacists, healthcare providers, and patients remains an important part of safe compounded prescriptions. Compounding pharmacists review prescriptions carefully, confirm dosing instructions, and evaluate ingredient compatibility before preparation begins. This collaborative approach supports medication safety by reducing the risk of errors and ensuring treatments meet individual patient needs.
The article concludes that sterile compounding continues to play an important role in healthcare, particularly for patients requiring customized therapies that are unavailable through traditional manufacturing channels. Whether preparing IV medications, injectable therapies, or other sterile compounded medications, pharmacies rely on contamination prevention procedures and strict preparation standards to support patient care. The article notes that understanding how sterile compounding works can help patients feel more informed about the safety measures involved in preparing specialized medications.
What Sterile Compounding Means for Medication Safety features insights from Laura Temple, a compounding pharmacist expert at Laura’s Pharmacy in Azle, Texas, on HelloNation.
About HelloNation
HelloNation is America’s Good News Network, a premier media platform built on the idea that good news travels faster when real people tell real stories. Through its community-focused publications and innovative “edvertising” approach, HelloNation delivers content that informs, inspires, and spotlights the leaders making a meaningful impact in their communities.
View original content to download multimedia:https://www.prnewswire.com/news-releases/hellonation-article-highlights-sterile-compounding-and-medication-safety-with-insights-from-compounding-pharmacist-expert-laura-temple-302831275.html
SOURCE HelloNation
Technology
CIOs Forced to Rethink Manual Compliance Processes as Regulatory Complexity Rises, Says Info-Tech Research Group
Published
8 minutes agoon
July 21, 2026By
Regulatory demands are increasing in volume, complexity, and speed, leaving many organizations reliant on fragmented, manual approaches that slow response times and increase risk. New insights from Info-Tech Research Group show that organizations need to adopt more structured and scalable approaches to keep pace with regulatory change. The firm’s recently published blueprint, Build a Regulatory IT Response Engine, provides frameworks, tools, and step-by-step guidance to help organizations translate regulatory requirements into actionable IT controls and prioritized initiatives.
ARLINGTON, Va., July 21, 2026 /PRNewswire/ — Growing regulatory pressure across jurisdictions is forcing organizations to rethink how they interpret, prioritize, and execute compliance requirements. Many IT teams continue to operate with inconsistent processes and limited coordination, resulting in delayed initiatives and increased exposure to financial and reputational risk. Info-Tech’s blueprint, Build a Regulatory IT Response Engine, introduces a coordinated and repeatable approach to help IT leaders operationalize compliance and improve execution outcomes.
Info-Tech’s findings indicate that while organizations recognize the need for faster and more consistent regulatory response, they continue to face barriers such as fragmented interpretation of requirements, weak prioritization, and limited scalability. AI-enabled tools can help streamline analysis and accelerate response planning, but without a coordinated approach grounded in governance and human oversight, those benefits are difficult to realize.
“Regulatory response is becoming too complex to manage through disconnected, manual processes,” says Ahmad Jowhar, senior research analyst at Info-Tech Research Group. “IT leaders need a repeatable way to interpret requirements, prioritize action, and use AI to accelerate planning without losing the governance and oversight needed to execute effectively.”
Key Challenges IT Leaders Face in Regulatory Response
Despite ongoing investments in compliance, organizations continue to face systemic challenges that hinder effective execution. Info-Tech’s blueprint highlights several areas where IT and compliance leaders struggle most:
Fragmented and manual processes that slow regulatory interpretation and response.Inconsistent application of regulatory requirements across teams and jurisdictions.Poor prioritization of IT initiatives, leading to missed deadlines and duplicated effort.Limited scalability to manage increasing regulatory volume and complexity.Misalignment between compliance activities and broader business priorities.
Info-Tech’s Framework for Building a Regulatory IT Response Engine
To address these challenges, Info-Tech recommends a structured, AI-enabled approach that improves consistency, speed, and scalability. The firm’s Build a Regulatory IT Response Engine blueprint outlines the following key priorities for IT leaders:
Define the regulatory landscape: Establish organizational context, governance structures, and a centralized inventory of applicable regulations.Translate requirements into IT controls: Use AI-enabled analysis and structured assessments to convert regulatory obligations into actionable controls.Prioritize IT initiatives: Align initiatives based on cost, effort, impact, and regulatory timelines to reduce execution risk.Build and communicate a roadmap: Develop a clear, resource-aligned roadmap to guide execution and stakeholder alignment.Establish a repeatable process: Continuously monitor, adapt, and refine regulatory response capabilities to maintain compliance over time.
Organizations that adopt this structured approach can move from reactive compliance efforts to a more proactive and scalable model that shortens response timelines, reduces manual effort, and strengthens execution.
The firm’s Build a Regulatory IT Response Engine blueprint includes practical tools such as a Regulation Inventory Tool, a Regulatory Response IT Action Plan Tool, a Communication Deck Template, and a Compliance Program Framework. By applying these resources, IT leaders can standardize regulatory responses, improve prioritization, and help ensure compliance initiatives are executed on time and in alignment with business priorities.
For exclusive and timely commentary from Info-Tech’s experts, including Ahmad Jowhar, and access to the complete Build a Regulatory IT Response Engine blueprint, please contact pr@infotech.com.
About Info-Tech Research Group
Info-Tech Research Group is the “get things done” partner for over 30,000 IT, HR, and marketing leaders worldwide. The fastest growing research and advisory firm, Info-Tech enables leaders to make well-informed decisions and transform their organizations through AI, strategic foresight, step-by-step methodologies, practical tools, industry-leading advisory, and training programs. For nearly 30 years, tens of thousands of private and public organizations have trusted Info-Tech to lead their most important initiatives through periods of change and deliver outcomes that truly matter.
To learn more about Info-Tech’s HR research and advisory services, visit McLean & Company, and for data-driven software buying insights and vendor evaluations, visit the firm’s SoftwareReviews platform.
Media professionals can register for unrestricted access to research across IT, HR, and software and hundreds of industry analysts through the firm’s Media Insiders program. To gain access, contact pr@infotech.com.
For information about Info-Tech Research Group or to access the latest research, visit infotech.com and connect via LinkedIn and X.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cios-forced-to-rethink-manual-compliance-processes-as-regulatory-complexity-rises-says-info-tech-research-group-302831286.html
SOURCE Info-Tech Research Group
Technology
Atomera to Announce Second Quarter 2026 Financial Results and Host Webinar on Tuesday, August 4, 2026
Published
8 minutes agoon
July 21, 2026By
LOS GATOS, Calif., July 21, 2026 /PRNewswire/ — Atomera Incorporated (NASDAQ: ATOM), a semiconductor materials and technology licensing company, announced today that it plans to release its second quarter 2026 financial results after the market closes on Tuesday, Aug. 4, 2026.
The company will host a live video Zoom webinar at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) on Tuesday, Aug. 4, 2026, to discuss the results. The live webinar can be accessed through Atomera’s investor relations website at https://ir.atomera.com. A replay of the webcast will be available for 12 months. To pre-register for the webinar, use the following link.
https://atomera.zoom.us/webinar/register/WN_OJFbTWe1SIyV69LLdDadCw
About Atomera
Atomera Incorporated is a semiconductor materials and technology licensing company focused on deploying its proprietary, silicon-proven technology into the semiconductor industry. Atomera has developed Mears Silicon Technology™ (MST®), which increases performance and power efficiency in semiconductor transistors. MST can be implemented using equipment already deployed in semiconductor manufacturing facilities and is complementary to other nano-scaling technologies already in the semiconductor industry roadmap. More information can be found at www.atomera.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/atomera-to-announce-second-quarter-2026-financial-results-and-host-webinar-on-tuesday-august-4-2026-302830602.html
SOURCE Atomera Incorporated
HelloNation Article Highlights Sterile Compounding and Medication Safety With Insights From Compounding Pharmacist Expert Laura Temple
CIOs Forced to Rethink Manual Compliance Processes as Regulatory Complexity Rises, Says Info-Tech Research Group
Atomera to Announce Second Quarter 2026 Financial Results and Host Webinar on Tuesday, August 4, 2026
Send Rakhi to UK swiftly with UK Gifts Portal
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
New Gooseneck Omni Antennas Offer Enhanced Signals in a Durable Package
Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap
Trending
-
Technology5 days agoTimed with the Canton Fair, Connexion ShenZhen 2026 Unveils Major Fourth-Edition Upgrades as a Greater Bay Area Mega Sourcing Event
-
Coin Market5 days agoBitcoin outlook improves amid 6% weekly gain: Can BTC bulls push higher?
-
Technology4 days agoGlobal Times: China sends fresh signal on global AI cooperation at WAIC
-
Coin Market4 days agoThe British Virgin Islands are a top crypto hub no one ever talks about: Here’s why
-
Coin Market5 days agoTrump teleprompter operator made $100K betting on Kalshi markets tied to speeches: ABC
-
Technology5 days agoGrand Bargain Project Announces Procedural Change that Will Turn Congress into a Problem-Solving Institution Within Days
-
Technology5 days agoDrake Expands End-to-End Professional Services with Launch of Drake Audit Defense™
-
Technology5 days agoTexas Instruments board declares third quarter 2026 quarterly dividend
